Adrenocortical carcinoma epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
The [[incidence]] of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data are lacking. A [[bimodal distribution]] was observed, the first one in pediatrics and the second one in the fifth to sixth decade. There is a predilection for the female gender. | The [[incidence]] of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data are lacking. A [[bimodal distribution]] was observed, the first one in pediatrics and the second one in the fifth to the sixth decade. There is a predilection for the female gender. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
| Line 10: | Line 10: | ||
=== Age === | === Age === | ||
* A [[bimodal distribution]] was observed, the first one in pediatrics and the second one in the fifth to sixth decade.<ref name="pmid19500769">{{cite journal| author=Fassnacht M, Allolio B| title=Clinical management of adrenocortical carcinoma. | journal=Best Pract Res Clin Endocrinol Metab | year= 2009 | volume= 23 | issue= 2 | pages= 273-89 | pmid=19500769 | doi=10.1016/j.beem.2008.10.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19500769 }}</ref> | * A [[bimodal distribution]] was observed, the first one in pediatrics and the second one in the fifth to the sixth decade.<ref name="pmid19500769">{{cite journal| author=Fassnacht M, Allolio B| title=Clinical management of adrenocortical carcinoma. | journal=Best Pract Res Clin Endocrinol Metab | year= 2009 | volume= 23 | issue= 2 | pages= 273-89 | pmid=19500769 | doi=10.1016/j.beem.2008.10.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19500769 }}</ref> | ||
=== Gender === | === Gender === | ||
Revision as of 15:06, 26 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma epidemiology and demographics |
|
FDA on Adrenocortical carcinoma epidemiology and demographics |
|
CDC on Adrenocortical carcinoma epidemiology and demographics |
|
Adrenocortical carcinoma epidemiology and demographics in the news |
|
Blogs on Adrenocortical carcinoma epidemiology and demographics |
|
Risk calculators and risk factors for Adrenocortical carcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3] Mohammed Abdelwahed M.D[4]
Overview
The incidence of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data are lacking. A bimodal distribution was observed, the first one in pediatrics and the second one in the fifth to the sixth decade. There is a predilection for the female gender.
Epidemiology and Demographics
Incidence
- The incidence of adrenocortical carcinoma is 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data are lacking.[1]
Age
- A bimodal distribution was observed, the first one in pediatrics and the second one in the fifth to the sixth decade.[2]
Gender
- There is a predilection for the female gender.[3]
- Girls are also more commonly affected than boys (1.6:1).[4]
References
- ↑ Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. doi:10.1210/jc.2005-2639. PMID 16551738.
- ↑ Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
- ↑ Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X; et al. (1990). "Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy". N Engl J Med. 322 (17): 1195–201. doi:10.1056/NEJM199004263221705. PMID 2325710.
- ↑ Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG; et al. (2004). "Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry". J Clin Oncol. 22 (5): 838–45. doi:10.1200/JCO.2004.08.085. PMID 14990639.